Clarivate

JUNE 26, 2023

Obtaining the preferences of patients and their caregivers is not a new concept in healthcare. Increasingly, however, industry guidance documents utilize the term ‘patient preference’ in relation to new drug development and benefit-risk assessment. Health technology assessment (HTA) bodies also have some appetite for this information.

Food and Drug Administration 52

Food and Drug Administration Patients Side effects Medicine 52

European Pharmaceutical Review

JULY 20, 2022

Monitoring and studying the side effects of licensed medicines is an essential part of drug development to ensure public safety. This is usually on a much larger scale than is possible in clinical trials and can uncover less common side effects. Supporting regulators. Study focus. almitrine – a respiratory stimulant.

Medicine 97

Medicine Safety Side effects Electronics 97

Medgadget

MAY 2, 2023

The system uses the patient’s EEG data to calculate a value for the amygdala-derived-EFP biomarker, and meanwhile the patient tries various mental strategies that may help to reduce the value. These treatments at times come with a long list of side effects, leaving many patients in search of an effective long-term solution.

Side effects 86

Side effects Prescription Healthcare Healthcare 86

European Pharmaceutical Review

DECEMBER 14, 2023

Our research showed that in Europe between 1999 and 2016, 35 products were withdrawn. They also include many of the common “exclusions” in RCTs, such as pregnant women, children, the elderly and patients on multiple medications. Meta-analyses contributed least frequently (31.4 As of October 2023, 62.93

Medicine 116

Medicine Safety Competition Medical 116

European Pharmaceutical Review

JUNE 12, 2024

The study included 92 adult patients with confirmed CDI. After treatment, patients were followed up at intervals of 72 hours, three weeks, eight weeks, three months and six months. Safety and quality of life of the patients participating in the study were also assessed. percent of those treated with fidaxomicin.

Safety 111

Safety Patients Side effects Management 111

pharmaphorum

JANUARY 6, 2023

It is estimated there are fewer than 1,000 patients with the disease in the US. Takeda said the drug is the first and only recombinant ADAMTS13 protein in development, and could become a crucial new treatment for patients with cTTP who currently have no therapies approved specifically to manage their condition.

Side effects 59

Side effects Patients Sales Management 59

Clarivate

SEPTEMBER 25, 2024

A ‘magic bullet’ medicine that can cure a disease quickly and completely, [1] without deleterious side effects. [2] 3 Patients required many injections over a long time period, and problems also arose from the galenic preparation of arsphenamide, which was insoluble in water.3

Medicine 59

Medicine Side effects Patients Pharmaceutical 59

European Pharmaceutical Review

NOVEMBER 4, 2022

tumour effects. Nevertheless, chemotherapy’s disadvantages, including substantial toxicities, combined with inconvenient hospital-based intravenous (IV) administration, impede patients’ ability to stay on treatment and their quality of life. The importance of taxanes in oncology. The future.

Food and Drug Administration 98

Food and Drug Administration Pharmaceutical FDA Patients 98

European Pharmaceutical Review

SEPTEMBER 5, 2024

Cancer-associated fibroblasts, and their effects of the immune activity in the tumour, are considered one of the main reasons why around four out of five patients do not benefit from immunotherapies such as checkpoint inhibitors. For the 28 patients who received only pembrolizumab, the OS was 58 percent.

Medicine 59

Medicine Side effects Marketing Patients 59

European Pharmaceutical Review

SEPTEMBER 22, 2023

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5

Food and Drug Administration 97

Food and Drug Administration Safety Patients Leads 97

PM360

AUGUST 26, 2024

Over time, as professional judgement led to experimentation to achieve the desired patient reported outcome (PRO) the need to close the loop with targeted treatment and diagnostics became more acute. By sequencing the genomes of over 1,000 patients, they have identified 20 new ultra-rare genetic conditions. Bright Spots.

Medicine 52

Medicine Food and Drug Administration Government Insurance 52

Pharmaceutical Technology

JUNE 20, 2023

Thematic Research [ii] shows that adoption of EMR systems is very high, especially in the US, and CDS systems are leveraging AI technology and available EMRs to provide clinical insight to both physicians and patients. In clinical trials, the use of plain language for participants is essential.

Electronics 52

Electronics Medical Training Healthcare 52